Lyu Ming, Wang Yue-Fei, Fan Guan-Wei, Wang Xiao-Ying, Xu Shuang-Yong, Zhu Yan
Tianjin State Key Laboratory of Modern Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, China.
Research and Development Center of TCM, Tianjin International Joint Academy of Biotechnology & Medicine, Tianjin, China.
Front Microbiol. 2017 Nov 8;8:2146. doi: 10.3389/fmicb.2017.02146. eCollection 2017.
It has become apparent that gut microbiota is closely associated with cardiometabolic diseases (CMDs), and alteration in microbiome compositions is also linked to the host environment. Next generation sequencing (NGS) has facilitated in-depth studies on the effects of herbal medicine and functional food on gut microbiota. Both herbal medicine and functional food contain fiber, polyphenols and polysaccharides, exerting prebiotics-like activities in the prevention and treatment of CMDs. The administrations of herbal medicine and functional food lead to increased the abundance of phylum Bacteroidetes, and genus and , while reducing phylum Firmicutes and Firmicutes/Bacteroidetes ratio in gut. Both herbal medicine and functional food interact with gut microbiome and alter the microbial metabolites including short-chain fatty acids (SCFAs), bile acids (BAs) and lipopolysaccharides (LPS), which are now correlated with metabolic diseases such as type 2 diabetes (T2D), obesity and non-alcoholic fatty liver disease (NAFLD). In addition, trimethylamine (TMA)-N-oxide (TMAO) is recently linked to atherosclerosis (AS) and cardiovascular disease (CVD) risks. Moreover, gut-organs axes may serve as the potential strategy for treating CMDs with the intervention of herbal medicine and functional food. In summary, a balance between herbal medicine and functional food rich in fiber, polyphenols and polysaccharides plays a vital role in modulating gut microbiota (phylum Bacteroidetes, Firmicutes and Firmicutes/Bacteroidetes ratio, and genus and ) through SCFAs, BAs, LPS and TMAO signaling regarding CMDs. Targeting gut-organs axes may serve as a new therapeutic strategy for CMDs by herbal medicine and functional food in the future. This review aims to summarize the balance between herbal medicine and functional food utilized for the prevention and treatment of CMDs through modulating gut microbiota.
显而易见,肠道微生物群与心脏代谢疾病(CMDs)密切相关,微生物群组成的改变也与宿主环境有关。下一代测序(NGS)有助于深入研究草药和功能性食品对肠道微生物群的影响。草药和功能性食品都含有纤维、多酚和多糖,在预防和治疗CMDs方面发挥着类似益生元的作用。草药和功能性食品的施用导致肠道中拟杆菌门、属和属的丰度增加,同时降低厚壁菌门以及厚壁菌门与拟杆菌门的比例。草药和功能性食品都与肠道微生物群相互作用,并改变包括短链脂肪酸(SCFAs)、胆汁酸(BAs)和脂多糖(LPS)在内的微生物代谢产物,这些代谢产物现在与2型糖尿病(T2D)、肥胖症和非酒精性脂肪性肝病(NAFLD)等代谢疾病相关。此外,三甲胺(TMA)-N-氧化物(TMAO)最近与动脉粥样硬化(AS)和心血管疾病(CVD)风险相关。此外,肠-器官轴可能是通过草药和功能性食品的干预来治疗CMDs的潜在策略。总之,富含纤维、多酚和多糖的草药和功能性食品之间的平衡在通过SCFAs、BAs、LPS和TMAO信号调节肠道微生物群(拟杆菌门、厚壁菌门和厚壁菌门与拟杆菌门的比例,以及属和属)方面起着至关重要的作用,这与CMDs有关。靶向肠-器官轴可能在未来成为草药和功能性食品治疗CMDs的新治疗策略。本综述旨在总结用于通过调节肠道微生物群预防和治疗CMDs的草药和功能性食品之间的平衡。